CN109223744A - Sodium Houttuyfonate is in preparation for preventing and treating the application in diabetic cardiopathy product - Google Patents
Sodium Houttuyfonate is in preparation for preventing and treating the application in diabetic cardiopathy product Download PDFInfo
- Publication number
- CN109223744A CN109223744A CN201811325039.5A CN201811325039A CN109223744A CN 109223744 A CN109223744 A CN 109223744A CN 201811325039 A CN201811325039 A CN 201811325039A CN 109223744 A CN109223744 A CN 109223744A
- Authority
- CN
- China
- Prior art keywords
- product
- sodium houttuyfonate
- preparation
- diabetes
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 56
- HPPWMWCITPGPKK-UHFFFAOYSA-M sodium;1-hydroxy-3-oxododecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCC(=O)CC(O)S([O-])(=O)=O HPPWMWCITPGPKK-UHFFFAOYSA-M 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 31
- 239000008280 blood Substances 0.000 claims abstract description 31
- 230000037149 energy metabolism Effects 0.000 claims abstract description 16
- 150000002632 lipids Chemical class 0.000 claims abstract description 13
- 208000031229 Cardiomyopathies Diseases 0.000 claims abstract description 11
- 208000021908 Myocardial disease Diseases 0.000 claims abstract description 11
- 239000008103 glucose Substances 0.000 claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000013875 Heart injury Diseases 0.000 abstract description 8
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 6
- 229930186217 Glycolipid Natural products 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 230000005856 abnormality Effects 0.000 abstract description 5
- 230000033228 biological regulation Effects 0.000 abstract description 5
- 230000009467 reduction Effects 0.000 abstract description 4
- 230000003293 cardioprotective effect Effects 0.000 abstract description 2
- 230000012666 negative regulation of transcription by glucose Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 38
- 210000002966 serum Anatomy 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 21
- 230000000747 cardiac effect Effects 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 15
- 230000003387 muscular Effects 0.000 description 15
- 210000004165 myocardium Anatomy 0.000 description 15
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 14
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 13
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 10
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 9
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 8
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 229960000830 captopril Drugs 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 8
- 108700038399 PGC-1 Proteins 0.000 description 7
- 102000017946 PGC-1 Human genes 0.000 description 7
- 229950006790 adenosine phosphate Drugs 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- -1 phosphate compound Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108091006112 ATPases Proteins 0.000 description 5
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 5
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 5
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 5
- 229950007002 phosphocreatine Drugs 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- IOMXCGDXEUDZAK-UHFFFAOYSA-N chembl1511179 Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC1=NC=CS1 IOMXCGDXEUDZAK-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 235000020995 raw meat Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000003680 myocardial damage Effects 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 235000013717 Houttuynia Nutrition 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000758742 Saururaceae Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000718 qrs complex Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- XLYLQUQHYUOPIW-UHFFFAOYSA-N 3-oxo-Tetradecanal Chemical compound CCCCCCCCCCCC(=O)CC=O XLYLQUQHYUOPIW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000758794 Asarum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000008100 Brassica rapa Species 0.000 description 1
- 235000011292 Brassica rapa Nutrition 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- CHTUTNRSUGMGBL-UHFFFAOYSA-N C(CCCCCCCCC)(=O)CC=O.C(C)=O Chemical compound C(CCCCCCCCC)(=O)CC=O.C(C)=O CHTUTNRSUGMGBL-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoylacetaldehyde Natural products CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 240000003271 Leonurus japonicus Species 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000011479 upper respiratory tract disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Sodium Houttuyfonate in preparation for preventing and treating the application in diabetic cardiopathy product.Sodium Houttuyfonate can be used for preparing prevention and treatment diabetic cardiopathy, regulation energy metabolism of myocardial disorder, the product for improving Abnormality of Glycolipid Metabolism.The present invention is verified by experiments: (1) Sodium Houttuyfonate has preventive and therapeutic effect to diabetic cardiopathy, there is cardioprotective effect；(2) controllable energy metabolism of myocardial disorder；(3) can reduce diabetes causes blood lipid to increase, and has certain reduction blood glucose effect.There is good potential applicability in clinical practice in terms of preparing the product for preventing and treating heart injury caused by diabetes, energy metabolism of myocardial disorder, Abnormality of Glycolipid Metabolism etc..
Description
Technical field
Belong to doctor for preventing and treating the application in diabetic cardiopathy product in preparation the present invention relates to a kind of Sodium Houttuyfonate
Medicine technical field.
Background technique
(1) diabetic cardiopathy complication and epidemiological survey
Diabetes are one of most important non-communicable diseases of current threat human health, sugar in China 20 years old or more crowd
Patient about 9.7% is urinated, the ratio of prediabetes wherein only has 40% patient to be diagnosed (Chinese medical up to 15.5%
Meeting diabetology branch Type 2 Diabetes In China guideline of prevention and treatment (version in 2013) Chinese medicine forward position magazine (electronic edition), 2015,
(03):26-89.).Diabetic cardiopathy (diabetic cardiopathy) is the most important complication of diabetes, in glycosuria
Suffer from cardiac complication in patient in 75% or so (Ofstad AP.Myocardial dysfunction and
cardiovascular disease in type 2 diabetes.Scand J Clin Lab Invest,2016,76(4):
271-81.), main performance includes caused by Leonurus heterophyllus sweet, coronary heart disease, diabetic heart autonomic nervous dysfunction
Arrhythmia cordis, cardiac insufficiency etc., be Life Quality of Diabetes Mellitus major influence factors and lethal first cause, suffer from
The risk of person's cardiovascular and cerebrovascular disease increases 2-4 times compared with non-diabetic people, and average life span reduces 8 years or so, because of diabetic heart
The sick and dead 60-70% (Luthra S, Leiva-Ju á rez MM, the Taggart that account for about diabetic's death toll
DP.Systematic review of therapies for stable coronary artery disease in
diabetic patients.Ann Thorac Surg,2015,100(6):2383-97.)。
It is controlled in a manner of islet secretion etc. based on the Primary Cares such as blood glucose level by supplementing insulin or correcting at present, however it is single
Pure glycemic control is limited for reducing the damage of diabetic's cardiovascular and cerebrovascular and the effect of caused mortality risk, clinically right
The patient of diabetic cardiopathy is had developed into there are no effective treatment method, heart injury once is difficult to reverse.
(2) the energy metabolism of myocardial disorder of diabetic cardiopathy and regulation
Heart is the organ of highly energy-consuming, and high energy phosphate compound (such as ATP) concentration stored in cardiac muscle cell is extremely low, required
Energy needs cardiac muscle cell that nutriment in blood is constantly generated ATP supply through oxidative phosphorylation by complicated link.Usually exist
Before diabetes diagnosis, cardiovascular pathological changes are had occurred and that, under the induction of the factors such as high glucose and high fat and insulin deficit or resistance, are passed through
Various Complex mechanism ultimately causes capilary, myocardial ultramicrostructure function changes, in the complex mechanism of in-between process, myocardium energy
Measuring metabolic disorder is center link and initiating agent (Fuentes-Antr á s J, Picatoste B, Ram í rez E, et
al.Targeting metabolic disturbance in the diabetic heart.Cardiovasc Diabetol,
2015,14:17.), when being cardiac function exception pathophysiological process earliest events, energy substrate transports the obstacle utilized, ginseng
Enter intracellular amount with the glucose that energy matter generates to reduce, and then switchs to mainly be drawn by fatty acid beta oxidation supplying energy
It plays lipid metaboli toxic metabolic products such as free fatty acid to increase, cardiac function is caused to be damaged (Tillquist MN, Maddox
TM.Update on diabetic cardiomyopathy:inches forward,miles to go.Curr Diab Rep,2012,12(3):305-13.)；In oxidative phosphorylation link, mitochondria is main organelle, and diabetes can cause the heart
The damage of muscle mitochondrial, the disorder for causing cardiac energy to be metabolized cause the impaired of contractile function.Therefore, cardiac energy is metabolized
Disorder, through the entire development process of diabetes-induced heart injury.
(3) Sodium Houttuyfonate
This product is Chinese medicine Saururaceae (Saururaceae) heartleaf houttuynia category (Houttuynia cordata Thunb) plant fish
The major volatile constituents decanoy acetaldehyde (decanoyl acetaldehyde) and sodium hydrogensulfite addition product of raw meat grass, chemical name decanoyl acetaldehyde close sulfurous
Sour hydrogen sodium.Clinically it is mainly used for chronic bronchitis and other infection of the upper respiratory tract diseases etc. at present.Pharmacological action is main
There was only faint antibacterial action to bacterium, there is certain inhibition to staphylococcus aureus, haemophilus influenzae, candida albicans etc.
Effect.To the effect of heart injury caused by diabetes, improvement glycolipid metabolism and improve energy metabolism of myocardial about Sodium Houttuyfonate
The research of aspect does not have been reported that.Also it there are no the patent of invention acted on about Sodium Houttuyfonate in this aspect.
Summary of the invention
It is an object of the present invention to provide a kind of new application of Sodium Houttuyfonate, new application refers to Sodium Houttuyfonate for preventing and treating
Heart disease complication caused by diabetes, regulation energy metabolism of myocardial disorder, improve diabetes caused by Abnormality of Glycolipid Metabolism with
And the raised product of blood lipid caused by other reasons.Technical solution of the present invention is specifically described as follows.
Sodium Houttuyfonate is in preparation for preventing and treating the application in diabetic cardiopathy product.
Application in blood glucose rise product caused by Sodium Houttuyfonate prevents and treats diabetes in preparation.
Blood lipid raising caused by Sodium Houttuyfonate prevents and treats diabetes in preparation and the application in diseases related product.
Application in energy metabolism of myocardial disorder product caused by Sodium Houttuyfonate improves diabetes in preparation.
The said goods include the substance of chemical structure identical as Sodium Houttuyfonate, and with the mutually isostructural object of decanoy acetaldehyde
Matter.
Above-mentioned product includes one of drug, preparation or health care product.
It can also include acceptable carrier pharmaceutically or in bromatology in above-mentioned product.
The dosage form of above-mentioned product can be it is diversified, as long as it is intracorporal that active constituent can be made effectively to reach
Dosage form is all possible.For example it can be selected from: tablet, capsule, powder, granule, syrup, solution, suspension, injection, tincture
The sustained-release dosage types such as the common dosage forms such as agent, oral solution, aerosol, mouth containing agent, electuary, pill, powder or nanometer formulation.
Effective administration dosage of active material of the present invention can be with the tight of mode of administration and disease to be treated used
Weight degree and change.In preparation for preventing and treating heart injury caused by diabetes, energy metabolism of myocardial disorder, Abnormality of Glycolipid Metabolism
Deng product in terms of have good potential applicability in clinical practice.
Specific embodiment
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.
The modeling method for the diabetes that the present invention is had been widely used using domestic and international academia, it is main using intraperitoneal injection chain
Urea helps rhzomorph 85mg/kg induction and generates blood glucose rise, further induces the rat model of heart injury and cardiac dysfunction.Mould
Quasi- clinical oral administration administration route, gives Sodium Houttuyfonate to animal pattern using stomach-filling mode and intervenes.
With whether succeeding for blood glucose level evaluation diabetes model；Rat blood sugar, blood lipid level are measured at the end of experiment, are surveyed
Determine ECG Change, detection heart failure marker (serum BNP, AST, ALT are horizontal) measures response to oxidative stress index of correlation, the heart
The variation of muscle mitochondrial ion channel relevant enzyme；Measure energy metabolism of myocardial correlation high energy phosphate compound and energetic supersession letter
The change of number passageway related genes, to evaluate drug effectiveness.
Embodiment 1: Sodium Houttuyfonate studies diabetes rat cardioprotection
Experimental material
1. drug and preparing streptozotocin (Streptozocin, lot number: WXBC4439V), German Sigma-alorich
Products；Sodium Houttuyfonate (lot number: 06161204, content is greater than the 93.0% of labelled amount, meets States Pharmacopoeia specifications), Brassica rapa L
Flat pharmaceutical Co. Ltd's product；Captopril (lot number: AAP7365), Shanghai Shi Guibao pharmaceutical Co. Ltd of Sino-U.S. product.Fish raw meat
Careless element sodium and captopril are dissolved using preceding with distilled water, and 0.1mol/L lemon is dissolved in when streptozotocin is using preceding use
In sour acid buffer (10mg/mL), it is protected from light, matching while using.
2. animal health male rat (Sprague Dawley 200-220g), cleaning grade, purchase is in Shanghai Si Laike reality
Animal Co., Ltd is tested, animal productiong licensing number: SCXK (Shanghai) 2012-0002.All rat feedings are in temperature 22-24
DEG C, in the environment of humidity 40-45% and 12 hours alternate Dark and Lights, free water and feed.The use of experimental animal
Follow experimental animal nursing and guide for use (the NIH Publication No.85-23,1996) of U.S. National Institutes promulgation
With the regulation of Shanghai Univ. of Traditional Chinese Medicine's animal care and the committee of use.
Experimental method
1. model preparation method rat is randomly divided into Normal group and modeling group.After fasting 12 hours, modeling group rat
Streptozotocin (being dissolved in the sodium citrate buffer solution that pH value is 4.5) solution of disposable celiac injection 1%, dosage are
85mg/kg, rats in normal control group inject equivalent sodium citrate buffer solution.After injection STZ 3 days, Roche blood glucose meter (moral is used
State) detection each group rat fasting blood-glucose (FBG).The rat of FBG >=16.7mmol/L is diabetic animal.
2. diabetic animal models are randomly divided into diabetes group, Captopril group (50mg/ by grouping and medication
Kg), Sodium Houttuyfonate small dose group (50mg/kg), Sodium Houttuyfonate large dosage group (100mg/kg), Normal group and model
Group rat oral gavage gives distilled water, remaining each group rat according to dosage distinguishes gastric infusion, administered volume 1mL/100g, and daily one
It is secondary, successive administration 26 days.
3. at the end of experiment with sample collection method, after Rat Fast 12 hours, weigh in (BM) for animal processing,
Urethane anesthesia (1g/kg) is injected intraperitoneally in all rats, records electrocardiogram (ECG).After abdominal aortic blood, 1972g's
10 minutes collection serum is centrifuged under speed；Left ventricular mass (LVM) is weighed after isolating cardiac tissue, and calculates left heart weight index
(LVMI=LVM/BM), heart tissue is stored in spare in -80 DEG C of refrigerator with serum.
4. observation index and detection method
The measurement of 4.1 fasting blood sugars: measuring FBG in each group rat blood serum using 7080 Biochemical Analyzer of Hitachi, according to
Measurement result evaluates the fasting blood glucose level of each group rat.
The measurement of 4.2 blood lipid levels: the content of Triglycerides in Serum (TG) and total cholesterol (TC) is raw using Hitachi 7080
Change analyzer to measure；Serum LDL cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) level make
It is detected in microplate reader with corresponding reagent box, operation follows kit specification.
The measurement of 4.3 Content of MDA: use kit with microplate reader using MDA content in DTNB method detection serum.Specifically
Operation follows kit specification.
The detection of 4.4 heart injury markers: using 7080 Biochemical Analyzer of Hitachi to serum alanine aminotransferase
(ALT), aspartate amino transferase (AST) is detected.With BNP content in enzyme-linked immunosorbent assay serum, press
Kit specification is operated.
The assessment of 4.5 electrocardiograms: Rat Ecg is recorded using RM6240B type multichannel bio signal system.Count the heart
Rate, P-R, QRS wave section, S-T and Q-T interphase evaluate the change of each group Rat Ecg.
The measurement of 4.6 cardiac muscular tissue's atpase activities: after ventricular homogenate, myocardium group is measured with fixing phosphorus method with microplate reader
Knit atpase activity in homogenate, including Na+-K+- ATPase and Ca2+-Mg2+-ATPase.Operating procedure follows kit explanation
Book.
The measurement of 4.7 cardiac muscular tissues total adenosine and phosphocreatine content: the 0.4mol/L perchloric acid solution prepared is pre-chilled,
It is then placed in cardiac muscular tissue to be homogenized, takes supernatant after low-temperature centrifugation (12000rpm, 15min, 4 DEG C), use disodium hydrogen phosphate
Solution adjusts pH value to neutrality, and the 15min centrifuging and taking supernatant again under low temperature obtains myocardium group that concentration is 92.31mg/mL
Knit homogenate.It is horizontal with the energy matter in high effective liquid chromatography for measuring heart tissue.The mobile phase A used is methanol-phosphorus
Phthalate buffer (10mmol/L, pH=6.2), B is water/methanol/acetonitrile (2:1:1, v/v/v) mixed solution, using gradient
Elution；Detection wavelength is 210nm, 254nm；Column temperature is 15 DEG C；Sample volume is 5 μ L.Testing index includes phosphocreatine
(phosphocreatine, PCr), atriphos (adenosine triphosphate, ATP), adenosine diphosphate (ADP)
(asenosine diphosphate, ADP) and adenosine monophosphate (adenosine monophosphate, AMP), and calculate total
Adenylic acid (total adenine nucleotides, TAN, TAN=ATP+ADP+AMP) and AMP/ATP ratio.
The measurement of the mRNA expression of AMPK- α 2, PPAR- α and PGC-1 α in 4.8 pairs of cardiac muscular tissues: total serum IgE in heart tissue
Extraction use fresh animal tissue and cell total rna extraction agent box, use 2XComSYBR qPCR Mix (ROX+) reagent
Box detects the mRNA expression of AMPK- α 2 in cardiac muscular tissue, PPAR- α, PGC-1 α and reference gene (Actb), and all operations follow
Kit specification.Primer sequence used in experiment see the table below:
1 PCR primer sequence of table
4.9 statistical analysis techniques: all data are indicated in the form of mean ± standard error.Homogeneity of variance person, using list
Analysis of variance compares two-by-two using LSD method, heterogeneity of variance person between group, using rank sum test, uses 21.0 software of SPSS
Statistics, P < 0.05 is considered as with statistical difference.
Experimental result
1. fasting blood glucose level each group rat fasting blood-glucose is horizontal as shown in table 2.Compared with Normal group, model group
The fasting blood glucose level of rat is significantly raised (P < 0.01)；Compared with model group, after administration 26 days, 100mg/kg Sodium Houttuyfonate
Group rat fasting blood-glucose level is substantially reduced (P < 0.01).Prompt Sodium Houttuyfonate has certain reduction blood glucose effect.
2 fasting blood sugar of table (N=8)
Ratio is organized with normal,##P < 0.01, and model group ratio,**P<0.01.
2. the blood lipid level of blood lipid level each group rat is as shown in table 3.Compared with Normal group, model group rats blood
The horizontal significant raising (P < 0.01) of TG, TC, LDL-C and HDL-C in clear.After drug treatment 26 days, captopril can be substantially reduced
TG and LDL is horizontal (P < 0.05, P < 0.01) in rat blood serum；The Sodium Houttuyfonate of 50mg/kg and 100mg/kg can all reduce greatly
TG, TC, HDL and LDL level (P < 0.05, P < 0.01) in mouse serum.Show that Sodium Houttuyfonate is substantially reduced blood lipid.
3 blood lipid level of table (N=8)
Ratio is organized with normal,##P < 0.01, and model group ratio,*P<0.05,**P<0.01.
3. the influence of pair myocardial injury markers, compared with Normal group, BNP content is significant in model group rats serum
It increases, the activity of serum alt and AST increase (P < 0.01)；After administration 26 days, captopril and Sodium Houttuyfonate can all be reduced
The raising (P < 0.01) of BNP content in rat blood serum caused by diabetes；Captopril and 50mg/kg Sodium Houttuyfonate can reduce
Serum alt caused by diabetes and the active raising (P < 0.01, P < 0.05) of AST；100mg/kg Sodium Houttuyfonate can reduce
The activity (P < 0.05) of ALT in rat blood serum.The results are shown in Table 4.Show that Sodium Houttuyfonate can be obviously to anti-myocardial
Damage.
4 Serum fibrosis markers of table and biomarker result (N=8)
Ratio is organized with normal,##P < 0.01, and model group ratio,*P<0.05,**P<0.01.
4. electrocardiogram such as table 5-1 shown in 5-2, is tested latter stage, model group rats electrocardiogram shows P-R, QRS complex, S-T
With Q-T interphase obvious postpone (P < 0.01), and heart rate obviously slows down (P < 0.01)；After drug treatment 26 days, captopril and fish
The plain sodium of raw meat grass can all shorten P-R caused by diabetes and QRS complex interphase delay (P < 0.01), and energy reverting diabetes cause
Decreased heart rate (P < 0.01).
Table 5-1 Electrocardiograph index (N=7~8)
Ratio is organized with normal,#P<0.05,##P < 0.01, and model group ratio,**P<0.01.
Table 5-2 Electrocardiograph index (N=7~8)
Ratio is organized with normal,##P < 0.01, and model group ratio,**P<0.01.
5. Content of MDA is compared with Normal group, in model group rats serum MDA content significantly increase (P <
0.01)；Compared with model group, after drug treatment 26 days, captopril and Sodium Houttuyfonate can reduce MDA in rat blood serum
Content (P < 0.01), the results are shown in Table 6.Prompt Sodium Houttuyfonate can inhibit peroxidating caused by diabetes.
6 Content of MDA result of table (N=8)
Ratio is organized with normal,##P < 0.01, and model group ratio,**P<0.01.
At the end of 6. cardiac muscular tissue's atpase activity is tested, Na in model group rats cardiac muscular tissue+-K+- ATPase and Ca2 +-Mg2+- ATPase activity is significantly lower than Normal group (P < 0.01)；Compared with model group, after drug treatment 26 days, Kato
Ca in the rat heart muscle tissue of Puli's group and Sodium Houttuyfonate 50mg/kg dosage group2+-Mg2+- ATPase activity increase (P <
0.01, P < 0.05), Na+-K+- ATPase activity is without significant change, and the results are shown in Table 7.Show that Sodium Houttuyfonate passes through to the heart
The protection of muscle mitochondrial, the raising to atpase activity improve energy metabolism of myocardial.
7 cardiac muscular tissue's atpase activity of table (N=8)
Ratio is organized with normal,##P < 0.01, and model group ratio,**P<0.01.
7. energy matter level is compared with normal group in cardiac muscular tissue, after modeling 29 days, model group rats cardiac muscle group
The content for knitting middle ATP, ADP, AMP, TAN and PCr all significantly reduces (P < 0.01, P < 0.05)；It is general through Kato compared to model group
The content of ATP, ADP, TAN and PCr all significantly increase (P < 0.01) in the rat heart muscle tissue of benefit treatment；50mg/kg dosage
Sodium Houttuyfonate significantly increases the content (P < 0.01) of ATP, ADP, TAN and PCr in rat heart muscle tissue；100mg/kg dosage
Sodium Houttuyfonate significantly increase the content (P < 0.01) of ATP, ADP and TAN in rat heart muscle tissue, also, captopril
The AMP/ATP ratio of group and Sodium Houttuyfonate group significantly reduces (P < 0.01), the results are shown in Table 8-1,8-2.Show Sodium Houttuyfonate
Energy metabolism of myocardial has improvement result.
In table 8-1 cardiac muscular tissue total adenosine and phosphocreatine it is horizontal (N=8)
Ratio is organized with normal,#P<0.05,##P < 0.01, and model group ratio,**P<0.01.
In table 8-2 cardiac muscular tissue total adenosine and phosphocreatine it is horizontal (N=8)
Ratio is organized with normal,##P < 0.01, and model group ratio,**P<0.01.
8. the influence that AMPK- α 2, PPAR- α and PGC-1 α mRNA are expressed in pair cardiac muscular tissue is compared with normal group, model
AMPK- α 2 and PGC-1 α mRNA expression increases (P < 0.05) in the cardiac muscular tissue of group rat；Compared with model group, Captopril group
Cardiac muscular tissue AMPK- α 2 and PGC-1 α mRNA expression with Sodium Houttuyfonate 100mg/kg dosage group rat reduces (P < 0.05),
AMPK- α 2mRNA expression reduces (P < 0.05) in cordate houttuynia 50mg/kg dosage group rat heart muscle tissue.It the results are shown in Table 9.Show fish
The plain sodium of raw meat grass is improved diabetes by regulation AMPK signal path and causes energy metabolism of myocardial disorder to draw to antihyperglycemic
The myocardial damage risen or even heart failure.
The mRNA relative expression levels of AMPK- α 2, PPAR- α and PGC-1 α in 9 cardiac muscular tissue of table
The mRNA relative expression quantity of each group relative to the normal multiple for organizing expression quantity to indicate.Ratio is organized with normal,#P<
0.05, and model group ratio,*P<0.05.
It summarizes
By above-mentioned the results showed that showing hyperglycemia, hyperlipidemia, serum for diabetic cardiopathy rat model
The exception of myocardium enzyme and oxidative stress index, the slowing down of heart rate, the raising of the exception of electrocardiogram, serum brain natriuretic peptide in patients level；Cardiac muscle
Energetic supersession substance is abnormal, shows the generation of diabetic animal models myocardial damage, model success；Myocardial ATP enzymatic activity reduces,
The raising of myocardium AMPK α 2, PGC-1 α mRNA expression, hints model animal cardiac muscle mitochondrial damages and cardiac muscle AMPK access occur
Expression increases.And after Sodium Houttuyfonate is intervened, blood glucose reduces, oxidative stress and blood lipid level decline, myocardial damage, heart function
There can be improvement result, these effects that Sodium Houttuyfonate generates are adjusted by raising myocardium atpase activity and lowering AMP/ATP
AMPK access is controlled, and then regulates and controls energy metabolism of myocardial and reaches, for preventing and treating or delaying generation, the development of diabetic cardiomyopathy,
The incidence for reducing arrhythmia cordis caused by heart diabetes, blood-pumping function reduction etc. is of great significance and application value.
The present invention is verified by experiments: (1) Sodium Houttuyfonate has preventive and therapeutic effect to diabetic cardiopathy, there is Cardioprotective effect
Fruit；(2) controllable energy metabolism of myocardial disorder；(3) can reduce diabetes causes blood lipid to increase, and has certain reduction blood glucose to make
With.Preparing the product side for preventing and treating heart injury caused by diabetes, energy metabolism of myocardial disorder, Abnormality of Glycolipid Metabolism etc.
Face has good potential applicability in clinical practice.
Finally, need indicated herein be: the above is only the embodiment of the present invention, are served only for technical solution of the present invention
It is described in more detail, should not be understood as limiting the scope of the invention, those skilled in the art is according to this hair
Some nonessential modifications and adaptations that bright above content is made all belong to the scope of protection of the present invention.
Claims (6)
1. Sodium Houttuyfonate is in preparation for preventing and treating the application in diabetic cardiopathy product.
The application in blood glucose rise product caused by 2. Sodium Houttuyfonate prevents and treats diabetes in preparation.
Blood lipid raising caused by 3. Sodium Houttuyfonate prevents and treats diabetes in preparation and the application in diseases related product.
The application in energy metabolism of myocardial disorder product caused by 4. Sodium Houttuyfonate improves diabetes in preparation.
5. application described according to claim 1~one of 4, which is characterized in that product includes in drug, preparation or health care product
It is a kind of.
6. application described according to claim 1~one of 4, which is characterized in that further include pharmaceutically or in bromatology in product
Acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811325039.5A CN109223744A (en) | 2018-11-08 | 2018-11-08 | Sodium Houttuyfonate is in preparation for preventing and treating the application in diabetic cardiopathy product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811325039.5A CN109223744A (en) | 2018-11-08 | 2018-11-08 | Sodium Houttuyfonate is in preparation for preventing and treating the application in diabetic cardiopathy product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109223744A true CN109223744A (en) | 2019-01-18 |
Family
ID=65077603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811325039.5A Pending CN109223744A (en) | 2018-11-08 | 2018-11-08 | Sodium Houttuyfonate is in preparation for preventing and treating the application in diabetic cardiopathy product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109223744A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110403997A (en) * | 2019-08-30 | 2019-11-05 | 西安交通大学 | A kind of application of houttuynia extract as Adenylate cyclase activator in the drug that preparation improves metabolic syndrome |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108210487A (en) * | 2018-03-02 | 2018-06-29 | 武汉科技大学 | Application of the Sodium Houttuyfonate in treatment heart failure and/or antiarrhythmic medicament is prepared |
-
2018
- 2018-11-08 CN CN201811325039.5A patent/CN109223744A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108210487A (en) * | 2018-03-02 | 2018-06-29 | 武汉科技大学 | Application of the Sodium Houttuyfonate in treatment heart failure and/or antiarrhythmic medicament is prepared |
Non-Patent Citations (1)
| Title |
|---|
| 王海颖等: "鱼腥草改善糖尿病大鼠血脂代谢", 《中国中医基础医学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110403997A (en) * | 2019-08-30 | 2019-11-05 | 西安交通大学 | A kind of application of houttuynia extract as Adenylate cyclase activator in the drug that preparation improves metabolic syndrome |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1429602B1 (en) | Methods for treating disorders using plant extracts | |
| Pliml et al. | Effects of ribose on exercise-induced ischaemia in stable coronary artery disease | |
| AU2002335689A1 (en) | Methods for treating disorders using plant extracts | |
| CN107441078B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN108042554B (en) | Application of the ophiopogonin D on preparation treatment metabolic syndrome drug | |
| Ghalavand et al. | Effect of Exercise and Insulin Signaling on Glucose Transporter Type 4 in Skeletal Muscles: A narrative review | |
| EP2130533A1 (en) | Ataractic agent and functional food | |
| CN109223744A (en) | Sodium Houttuyfonate is in preparation for preventing and treating the application in diabetic cardiopathy product | |
| Suthar et al. | Efficacy and safety of PDM011011 capsules as compared to metformin in subjects with type-2 diabetes mellitus: An open-label, randomized, active-controlled, multicentric, phase III study | |
| US10849918B2 (en) | Composition for optic nerve protection | |
| EP1690519A1 (en) | Alpha-glucosidase activity inhibitor | |
| CN109200268A (en) | The composition and its long-time service method of weight gain compound | |
| CN108619137B (en) | Application of carbazole compounds in preparation of medicines for treating metabolic diseases and complications thereof | |
| Oparinde et al. | Effect of Moringa oleifera leaf extract on serum lipids and glycaemic control in alloxan induced diabetic albino rats | |
| CN107019778A (en) | It is a kind of that there is composition of fat-reducing and effect for reducing blood fat and preparation method thereof and purposes | |
| CN104968342B (en) | Sulforaphane for the insulin resistance for treating or reducing liver | |
| CN111249271A (en) | Medicament for treating diabetes and preparation method and application thereof | |
| CN105055399A (en) | Natural product composition for preventing and treating diabetes and application thereof | |
| CN111840331A (en) | Application of bear gall exosome in preparation of medicine for treating type II diabetes | |
| CN105232676B (en) | A kind of Chinese medicine for treating diabetes and preparation method thereof | |
| Hotta et al. | Effect of an aldose reductase inhibitor, SNK‐860, on deficits in the electroretinogram of diabetic rats | |
| CN108143756A (en) | A kind of plant hypoglycemic agent and preparation method thereof | |
| CN103193853A (en) | Compound and composition used for treating psoriasis, and preparation method thereof | |
| CN101138587A (en) | Application of white fleece-flower root or white fleece-flower root diketone A in the preparation of medicament for treating neurological disorders | |
| TWI723171B (en) | Use of a polysaccharide mixture for the manufacture of a medicament for treating hyperglycemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190118 |
|
| RJ01 | Rejection of invention patent application after publication |